Sigma Healthcare Limited (SIGGF)
| Market Cap | 24.05B +11.6% |
| Revenue (ttm) | 6.37B +208.9% |
| Net Income | 400.09M +97.1% |
| EPS | 0.04 -72.9% |
| Shares Out | n/a |
| PE Ratio | 60.12 |
| Forward PE | 41.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.213 |
| Previous Close | 2.213 |
| Day's Range | 2.213 - 2.213 |
| 52-Week Range | 1.810 - 2.348 |
| Beta | 0.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Sigma Healthcare
Sigma Healthcare Limited operates as a retail pharmacy franchisor and pharmaceutical wholesale and distributor to community pharmacies primarily in Australia. It offers support services to a network of franchised retail pharmacies; third and fourth party logistics services to pharmaceutical manufacturers and other supplier partners; and health services. The company operates stores under the Chemist Warehouse, Amcal, and Discount Drug stores brand names. It also offers products through online. The company was founded in 1912 and is headquartered... [Read more]
Financial Performance
In fiscal year 2025, Sigma Healthcare's revenue was 6.00 billion, an increase of 82.18% compared to the previous year's 3.29 billion. Earnings were 529.91 million, a decrease of -2.05%.
Financial numbers in AUD Financial StatementsNews
Sigma Healthcare stock jumps 8% after pulling out of billion-dollar Boots deal
Sigma Healthcare stock jumped on Monday after the Australian pharmacy group walked away from a potential deal to buy UK pharmacy chain Boots. The development looks like a rare case of investors reward...
Australia's Sigma Healthcare drops pursuit of UK pharmacy chain Boots
Australia's Sigma Healthcare said on Monday it had walked away from preliminary talks to buy British pharmacy chain Boots, concluding that a potential deal would not meet its strategic and capital...
Sigma Healthcare in preliminary discussions to buy Boots
The company said, “Sigma Healthcare (SIGGF) refers to the recent media speculation regarding the sale process of The Boots Group. Sigma continuously reviews opportunities that would create value for s...
Sigma Healthcare in Preliminary Talks to Buy U.K.'s Boots
Australia's Sigma Healthcare said it is involved in early discussions about a potential acquisition of U.K. drugstore chain Boots.
Sigma Healthcare initiated with a Sector Perform at RBC Capital
RBC Capital analyst Michael Toner initiated coverage of Sigma Healthcare (SIGGF) with a Sector Perform rating and A$2.50 price target The firm cites risks from the company’s early international expans...
Sigma Healthcare Earnings Call Transcript: H1 2026
Revenue grew 15% year-over-year, with strong domestic and international sales, and normalized EBIT up 18.7%. Integration synergies and disciplined cost control supported margin expansion, while GLP-1 medicines drove significant sales growth.
Sigma Healthcare Quarterly report: H1 2026
Sigma Healthcare has published its H1 2026 quarterly earnings report on February 25, 2026.
Sigma Healthcare Slides: H1 2026
Sigma Healthcare has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Sigma Healthcare Earnings release: H1 2026
Sigma Healthcare released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Sigma Healthcare initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sigma Healthcare (SIGGF) with a Buy rating and A$3.50 price target The firm sees upside the company’s margin estimates and the stock’s valuation. Published first…
Sigma Healthcare Transcript: AGM 2025
The AGM highlighted strong financial growth post-merger, upgraded synergy targets, and robust governance enhancements. Shareholders approved all resolutions, including director reelections and remuneration reports, while the board addressed integration, remuneration, and related party governance in detail.
Sigma Healthcare Slides: FY 2025
Sigma Healthcare has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 21, 2025.
Sigma Healthcare Earnings Call Transcript: H2 2025
Strong post-merger results with revenue up 82% and normalized EBIT up 41%. Store network expansion, own brand growth, and upgraded synergy targets drive performance, while integration and competitive pressures remain key focus areas.
Sigma Healthcare Annual report: H2 2025
Sigma Healthcare has published its H2 2025 annual report on September 8, 2025.
Sigma Healthcare Slides: H2 2025
Sigma Healthcare has posted slides in relation to its H2 2025 quarterly earnings report, which was published on September 8, 2025.
Sigma Healthcare Earnings release: H2 2025
Sigma Healthcare released its H2 2025 earnings on September 8, 2025, summarizing the period's financial results.
Sigma Healthcare Slides: Company Presentation
Sigma Healthcare has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2025.
Sigma Healthcare Press release: Trading Update
Sigma Healthcare issued a press release on May 5, 2025, disclosing material business information to investors.
Sigma Healthcare initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Lisa Deng initiated coverage of Sigma Healthcare (SIGGF) with a Neutral rating and A$2.70 price target The firm views Sigma as a vertically integrated retail pharmacy leader…
Sigma Healthcare Transcript: EGM 2025
Shareholders approved key resolutions for a transformative merger with Chemist Warehouse, including new board appointments, governance frameworks for related party transactions, and changes to executive equity plans. The merger aims to create a leading pharmacy group with significant cost synergies and growth opportunities.
Sigma Healthcare Slides: FY 2025
Sigma Healthcare has posted slides in relation to its FY 2025 quarterly earnings report, which was published on January 28, 2025.
Sigma Healthcare downgraded to Underperform from Hold at Jefferies
Jefferies downgraded Sigma Healthcare (SIGGF) to Underperform from Hold with a price target of A$1.85, up from A$1.60. Sigma advised that it expects the proposed merger with Chemist Warehouse implemen...
Sigma Healthcare Earnings Call Transcript: H1 2025
Revenue and profit surged on the back of the new Chemist Warehouse contract, with normalized NPAT up over 300% and EBIT up 20% year-over-year. Gross margin remains under pressure, but cost discipline and operational leverage are improving profitability. Guidance for FY25 normalized EBIT is AUD 50–60 million.
Sigma Healthcare Quarterly report: H1 2025
Sigma Healthcare has published its H1 2025 quarterly earnings report on September 24, 2024.
Sigma Healthcare Slides: H1 2025
Sigma Healthcare has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 24, 2024.